Research map: Machine learning and cox model–based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 − metastatic breast cancer: a multicenter real-world study

Back to the article

Papers in this map

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  2. Retrospective study on regional nodal irradiation after omission of axillary lymph node dissection in sentinel lymph node-positive breast cancer: a propensity score matching analysis · 2026 · Related
  3. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement · Professor Gary S. Collins · 2015 · 3202 citations · Cited by this paper
  4. Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care · 2026 · Related
  5. Palbociclib and Letrozole in Advanced Breast Cancer · Richard S. Finn · 2016 · 3063 citations · Cited by this paper
  6. Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib · 2026 · Related
  7. Random survival forests · Hemant Ishwaran · 2008 · 2582 citations · Cited by this paper
  8. Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer · 2026 · Related
  9. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update · Antonio C. Wolff · 2018 · 2542 citations · Cited by this paper
  10. Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study · 2026 · Related
  11. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial · Massimo Cristofanilli · 2016 · 1868 citations · Cited by this paper
  12. Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B) · 2026 · Related
  13. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer · Matthew Philip Goetz · 2017 · 1768 citations · Cited by this paper
  14. Age-stratified difference in patient-reported health-related quality of life following breast cancer surgery · 2026 · Related
  15. Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development · Ana Victoria Ponce Bobadilla · 2024 · 815 citations · Cited by this paper
  16. Rediscovering the Ciucci pathway: in-vivo evidence of a palmar lymphatic channel · 2026 · Related
  17. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer · Gabriel N. Hortobagyi · 2022 · 774 citations · Cited by this paper
  18. Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer · 2026 · Related
  19. Explainable machine learning can outperform Cox regression predictions and provide insights in breast cancer survival · Arturo Moncada‐Torres · 2021 · 348 citations · Cited by this paper
  20. A Gradient Boosting Algorithm for Survival Analysis via Direct Optimization of Concordance Index · Yifei Chen · 2013 · 144 citations · Cited by this paper
  21. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial · Pin Zhang · 2023 · 110 citations · Cited by this paper
  22. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer · Gabriel N. Hortobágyi · 2019 · 74 citations · Cited by this paper
  23. The Application and Comparison of Machine Learning Models for the Prediction of Breast Cancer Prognosis: Retrospective Cohort Study · Jialong Xiao · 2022 · 58 citations · Cited by this paper
  24. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis · Marta Bonotto · 2016 · 57 citations · Cited by this paper
  25. Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study · Leonardo Provenzano · 2025 · 44 citations · Cited by this paper
  26. CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis · Carolin Müller · 2022 · 41 citations · Cited by this paper
  27. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study · Debora Basile · 2021 · 40 citations · Cited by this paper
  28. Eligibility of real-world patients with metastatic breast cancer for clinical trials · Atul Batra · 2020 · 29 citations · Cited by this paper
  29. Comparison of machine learning methods versus traditional Cox regression for survival prediction in cancer using real-world data: a systematic literature review and meta-analysis · Yinan Huang · 2025 · 23 citations · Cited by this paper
  30. Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients · Binliang Liu · 2020 · 20 citations · Cited by this paper
  31. Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies · Federica Giugliano · 2025 · 19 citations · Cited by this paper
  32. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis · Lorenzo Gerratana · 2023 · 17 citations · Cited by this paper
  33. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population · Bo-Fang Chen · 2024 · 16 citations · Cited by this paper
  34. The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study · Chiara Molinelli · 2024 · 16 citations · Cited by this paper
  35. Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) · Yifan Chen · 2024 · 10 citations · Cited by this paper
  36. Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer · Binliang Liu · 2024 · 8 citations · Cited by this paper
  37. Survival nomogram for patients with de novo metastatic breast cancer based on the SEER database and an external validation cohort · Lizhi Ning · 2023 · 7 citations · Cited by this paper
  38. Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study · Renata Duchnowska · 2025 · 7 citations · Cited by this paper
  39. Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer · Tetsuhiro Yoshinami · 2025 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)